FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Andromeda Biotech

Evotec takes legal steps against Andromeda Biotech, Ltd.

19-Sep-2014 - Evotec AG announced after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®. On 08 September 2014, US-based Hyperion Therapeutics, Inc. ...

Evotec

Andromeda Biotech Initiates DIA-AID 2, a Confirmatory Phase 3 Study using DiaPep277, for the Treatment of Type 1 Diabetes

02-Jun-2010 - Andromeda Biotech Ltd. announced the initiation of its confirmatory phase III clinical study, DIA-AID 2 using DiaPep277®, Andromeda’s lead product, for the treatment of type 1 diabetes. Enrollment of patients has begun in the US as part of a global trial which will be conducted at 100 medical ...

pancreas

Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes

11-Sep-2009 - Andromeda Biotech Ltd. announced that it has completed patient recruitment in its’ current Phase III study using DiaPep277 for the treatment of Type 1 diabetes. The current clinical study includes 456 patients and is being conducted at 40 medical centers in Europe, South Africa, and Israel. ...

amino acids insulin pancreatic cells +3

Clal Biotechnology Industries and Teva Pharmaceuticals Solidify their Collaboration for Final Stage Development of Diabetes Drug

06-Dec-2007 - Clal Biotechnology Industries Ltd. announced recently that Andromeda Biotech Ltd., a wholly owned subsidiary of CBI, signed a Term Sheet with Teva to develop and commercialize DiaPep277, an innovative and advanced drug for the treatment of type 1 diabetes. According to the Term Sheet, Teva and ...

TEVA Teva Pharmaceutical